Want to see VTAK full AI Analyst Report?
Top Page
Catheter Precision
(NYSE MKT:VTAK)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.27
▲(27.14% Upside)
Action:Upgraded
Date:08/01/26
The score is primarily constrained by weak financial performance—very small revenue relative to a high cost base, extreme losses, and sustained negative free cash flow—alongside a clearly bearish technical trend with the stock far below major moving averages. Valuation is difficult to support with a negative P/E and no dividend yield provided. Corporate events modestly help the outlook via added capital and preferred refinancing, but do not offset the underlying profitability and cash-burn risks.
Positive Factors
Accelerating Revenue Growth
Revenue growth indicates increasing commercial traction for VIVO and suggests adoption is expanding from a small base. If this momentum continues, greater procedure volume and site utilization could improve operating leverage and help the company move toward scale.
Negative Factors
Severe Operating Losses
The company’s cost structure remains vastly larger than its current revenue base, producing substantial net and operating losses despite growth. Unless revenue scales materially or expenses are reduced, continued negative operating leverage will constrain reinvestment and weaken equity value.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Revenue growth indicates increasing commercial traction for VIVO and suggests adoption is expanding from a small base. If this momentum continues, greater procedure volume and site utilization could improve operating leverage and help the company move toward scale.
Read all positive factors
Catheter Precision (VTAK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.65M
Dividend YieldN/A
Average Volume (3M)2.01M
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth219.17%
EPS Growth90.58%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-7.33
Shares Outstanding18,972,050
10 Day Avg. Volume766,284
30 Day Avg. Volume2,010,623
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.28
Price to Sales (P/S)2.41
P/FCF Ratio-0.24
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit15.92
Enterprise Value/Ebitda-1.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-608
Revenue Forecast (FY)$10.20M
Catheter Precision Business Overview & Revenue Model
Company Description
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by ...
How the Company Makes Money
Catheter Precision generates revenue primarily from sales and/or usage-based arrangements related to its VIVO mapping system. This generally includes (1) capital or system-related revenue when sites acquire or deploy the VIVO platform and (2) recu...
Catheter Precision Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
35
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.92M | 819.00K | 420.00K | 442.00K | 14.00K | 22.00K |
| Gross Profit | 914.00K | 756.00K | 378.00K | 412.00K | -147.00K | -1.54M |
| EBITDA | -12.01M | -17.11M | -11.30M | -15.11M | -22.37M | -25.85M |
| Net Income | -12.66M | -17.18M | -16.64M | -70.57M | -26.86M | -25.07M |
Balance Sheet | ||||||
| Total Assets | 36.87M | 15.86M | 27.77M | 30.74M | 16.84M | 21.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.84M | 88.00K | 2.87M | 3.56M | 15.86M | 15.04M |
| Total Debt | 3.32M | 3.85M | 1.79M | 372.00K | 0.00 | 2.26M |
| Total Liabilities | 19.73M | 9.21M | 16.01M | 9.54M | 7.58M | 7.37M |
| Stockholders Equity | 17.56M | 7.05M | 11.76M | 21.19M | 9.26M | 13.67M |
Cash Flow | ||||||
| Free Cash Flow | -9.42M | -8.31M | -9.34M | -20.70M | -22.59M | -27.89M |
| Operating Cash Flow | -9.31M | -8.30M | -9.27M | -20.62M | -22.57M | -27.63M |
| Investing Cash Flow | -1.96M | 167.00K | -67.00K | -61.00K | 21.00K | 3.80M |
| Financing Cash Flow | 11.08M | 5.34M | 8.65M | 8.39M | 23.36M | 14.96M |
Catheter Precision Technical Analysis
Neutral
0.21
Price Trends
2.10
Negative
5.31
Negative
10.13
Negative
Market Momentum
-0.24
Negative
40.43
Neutral
70.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Neutral. The current price of 0.21 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 2.10, and below the 200-day MA of 10.13, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 40.43 is Neutral, neither overbought nor oversold. The STOCH value of 70.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VTAK.
Catheter Precision Risk Analysis
Catheter Precision disclosed 40 risk factors in its most recent earnings report. Catheter Precision reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Catheter Precision Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $21.12M | -1.18 | -816.25% | ― | -27.70% | 61.44% | |
50 Neutral | $10.47M | -0.52 | -123.09% | ― | ― | 87.54% | |
45 Neutral | $21.27M | -0.16 | -33.51% | ― | -89.02% | -107.75% | |
43 Neutral | $2.53M | >-0.01 | -605.75% | ― | 8.36% | 88.88% | |
41 Neutral | $28.65M | -0.02 | -123.66% | ― | 219.17% | 90.58% |
* Healthcare Sector Average
VTAK
Catheter Precision
1.62
-23.88
-93.65%
NUWE
Nuwellis
0.70
-136.50
-99.49%
AEMD
Aethlon Medical
6.09
-30.33
-83.28%
PAVM
PAVmed
2.68
-11.90
-81.64%
HSCS
Heart Test Laboratories, Inc.
3.77
0.04
1.07%
Catheter Precision Corporate Events
Business Operations and StrategyDelistings and Listing ChangesShareholder MeetingsStock Split
Catheter Precision Plans Reverse Split and Flyte Rebranding
Neutral
Oct 2, 2026
At the September 30, 2026 annual meeting, Catheter Precision’s stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the pool by 5,000,000 shares, and a one-time repricing of outstanding stock options to fair marke...
Business Operations and StrategyDelistings and Listing ChangesStock Split
Catheter Precision to Become Flyte Aviation with Reverse Split
Neutral
Sep 25, 2026
On September 24, 2026, Catheter Precision’s board approved changing the company name to Flyte Aviation, Inc. and implementing a 1‑for‑10 reverse stock split of its common stock, following prior shareholder approval of the split r...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Catheter Precision Raises Capital, Refinances Preferred Stock
Positive
Jul 31, 2026
On July 30, 2026, Catheter Precision closed a private placement of 2,821 shares of Series C-4 Convertible Preferred Stock, raising gross proceeds of $2.821 million from accredited investors exercising additional investment rights under a March 9, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.